Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway
详细信息 查看全文
- 作者：Annemiek M. van Maldegema ; a.m.van_maldegem@lumc.nl" class="auth_mail" title="E-mail the corresponding author ; Judith V.M.G. Bové ; eb ; j.v.m.g.bovee@lumc.nl" class="auth_mail" title="E-mail the corresponding author ; Elleke F.P. Peterseb ; e.f.p.peterse@lumc.nl" class="auth_mail" title="E-mail the corresponding author ; Pancras C.W. Hogendoornb ; p.c.w.hogendoorn@lumc.nl" class="auth_mail" title="E-mail the corresponding author ; Hans Gelderbloma ; a.j.gelderblom@lumc.nl" class="auth_mail" title="E-mail the corresponding author
- 关键词：Ewing sarcoma ; IGF-1R ; PARP pathway ; Bone tumour ; Soft tissue tumour ; Sarcoma
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：53
- 期：Complete
- 页码：171-180
- 全文大小：549 K
文摘
- ass="listitem" id="list_ulist0010">
- ass="label">•
Preclinical studies show insulin-like growth factor 1 receptor (IGF-1R) and poly-ADP-ribose-polymerase (PARP) to be targets for Ewing sarcoma.
- ass="label">•
It is very important to understand the biological rationale for patient selection.
- ass="label">•
Therapeutic strategies with IGF-1R or PARP should definitely be explored further.